This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!
This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?
This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?
The summer book club started in 2015, with one of the best books we have done in book club, Atul Gawande's Being Mortal. I think it should be required reading for all physicians. So now, in 2025, it is the NephJC Summer Book’s tenth anniversary (which represents our eleventh book). The history has been rich:
This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!
Would a new drug option for resistant hypertension get you excited? How about a superior trial design?
— Nephrology Journal Club (@NephJC) December 9, 2022
Time to learn about PRECISION - our twitter journal club had 720 tweets, but you can catch the highlights quickly with the regular #TenTweetNephJC thread👇 pic.twitter.com/YH1P4rCIRG